Prion protein self-interaction in prion disease therapy approaches

被引:1
|
作者
Rigter, Alan [1 ]
Priem, Jan [1 ]
Langeveld, Jan P. M. [1 ]
Bossers, Alex [1 ]
机构
[1] Cent Vet Inst Wageningen UR, Dept Infect Biol, Lelystad, Netherlands
关键词
prion protein; prion; conversion; binding domains; self-interaction; prion disease therapy; CREUTZFELDT-JAKOB-DISEASE; IN-VITRO CONVERSION; SUSCEPTIBILITY-LINKED POLYMORPHISMS; BOVINE SPONGIFORM ENCEPHALOPATHY; NATURAL SCRAPIE; INSERT MUTATION; CELL-CULTURES; PRP GENOTYPES; CLOSED FLOCK; PRNP GENE;
D O I
10.1080/01652176.2011.604976
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Transmissible spongiform encephalopathies (TSEs) or prion diseases are unique disorders that are not caused by infectious micro-organisms (bacteria or fungi), viruses or parasites, but rather seem to be the result of an infectious protein. TSEs are comprised of fatal neurodegenerative disorders affecting both human and animals. Prion diseases cause sponge-like degeneration of neuronal tissue and include (among others) Creutzfeldt-Jacob disease in humans, bovine spongiform encephalopathy (BSE) in cattle and scrapie in sheep. TSEs are characterized by the formation and accumulation of transmissible (infectious) disease-associated protease-resistant prion protein (PrPSc), mainly in tissues of the central nervous system. The exact molecular processes behind the conversion of PrPC into PrPSc are not clearly understood. Correlations between prion protein polymorphisms and disease have been found, however in what way these polymorphisms influence the conversion processes remains an enigma; is stabilization or destabilization of the prion protein the basis for a higher conversion propensity? Apart from the disease-associated polymorphisms of the prion protein, the molecular processes underlying conversion are not understood. There are some notions as to which regions of the prion protein are involved in refolding of PrPC into PrPSc and where the most drastic structural changes take place. Direct interactions between PrPC molecules and/or PrPSc are likely at the basis of conversion, however which specific amino acid domains are involved and to what extent these domains contribute to conversion resistance/sensitivity of the prion protein or the species barrier is still unknown.
引用
收藏
页码:115 / 128
页数:14
相关论文
共 50 条
  • [1] Prion protein self-peptides modulate prion interactions and conversion
    Rigter, Alan
    Priem, Jan
    Timmers-Parohi, Drophatie
    Langeveld, Jan P. M.
    van Zijderveld, Fred G.
    Bossers, Alex
    BMC BIOCHEMISTRY, 2009, 10
  • [2] Prion protein and prion disease at a glance
    Zhu, Caihong
    Aguzzi, Adriano
    JOURNAL OF CELL SCIENCE, 2021, 134 (17)
  • [3] Approaches to therapy of prion diseases
    Weissmann, C
    Aguzzi, A
    ANNUAL REVIEW OF MEDICINE, 2005, 56 : 321 - 344
  • [4] Decreased cell surface prion protein in mouse models of prion disease
    Griffin, Jennifer K.
    Terry, Linda A.
    Jackman, Roy
    Yousefi, Masoud
    Cashman, Neil R.
    NEUROREPORT, 2007, 18 (01) : 1 - 6
  • [5] Prion protein interconversions
    Caughey, B
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 2001, 356 (1406) : 197 - 200
  • [6] Aberrant metal binding by prion protein in human prion disease
    Wong, BS
    Chen, SG
    Colucci, M
    Xie, ZL
    Pan, T
    Liu, T
    Li, RL
    Gambetti, P
    Sy, MS
    Brown, DR
    JOURNAL OF NEUROCHEMISTRY, 2001, 78 (06) : 1400 - 1408
  • [7] Prion Protein Functions and Dysfunction in Prion Diseases
    Sakudo, Akikazu
    Ikuta, Kazuyoshi
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (03) : 380 - 389
  • [8] Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development
    Vallabh, Sonia M.
    Nobuhara, Chloe K.
    Llorens, Franc
    Zerr, Inga
    Parchi, Piero
    Capellari, Sabina
    Kuhn, Eric
    Klickstein, Jacob
    Safar, Jiri G.
    Nery, Flavia C.
    Swoboda, Kathryn J.
    Geschwind, Michael D.
    Zetterberg, Henrik
    Arnold, Steven E.
    Minikel, Eric Vallabh
    Schreiber, Stuart L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (16) : 7793 - 7798
  • [9] Potential approaches for heterologous prion protein treatment of prion diseases
    Seelig, Davis M.
    Goodman, Patricia A.
    Skinner, Pamela J.
    PRION, 2016, 10 (01) : 18 - 24
  • [10] Therapeutic approaches in prion disease
    Hachiya, NS
    Sakasegawa, Y
    Kaneko, K
    JOURNAL OF HEALTH SCIENCE, 2003, 49 (04) : 267 - 272